

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	MAR 15	WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS	3	MAR 16	CASREACT coverage extended
NEWS	4	MAR 20	MARPAT now updated daily
NEWS	5	MAR 22	LWPI reloaded
NEWS	6	MAR 30	RDISCLOSURE reloaded with enhancements
NEWS	7	APR 02	JICST-EPLUS removed from database clusters and STN
NEWS	8	APR 30	GENBANK reloaded and enhanced with Genome Project ID field
NEWS	9	APR 30	CHEMCATS enhanced with 1.2 million new records
NEWS	10	APR 30	CA/CAPplus enhanced with 1870-1889 U.S. patent records
NEWS	11	APR 30	INPADOC replaced by INPADOCDB on STN
NEWS	12	MAY 01	New CAS web site launched
NEWS	13	MAY 08	CA/CAPplus Indian patent publication number format defined
NEWS	14	MAY 14	RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS	15	MAY 21	BIOSIS reloaded and enhanced with archival data
NEWS	16	MAY 21	TOXCENTER enhanced with BIOSIS reload
NEWS	17	MAY 21	CA/CAPplus enhanced with additional kind codes for German patents
NEWS	18	MAY 22	CA/CAPplus enhanced with IPC reclassification in Japanese patents
NEWS	19	JUN 27	CA/CAPplus enhanced with pre-1967 CAS Registry Numbers
NEWS	20	JUN 29	STN Viewer now available
NEWS	21	JUN 29	STN Express, Version 8.2, now available
NEWS	22	JUL 02	LEMBASE coverage updated
NEWS	23	JUL 02	LMEDLINE coverage updated
NEWS	24	JUL 02	SCISEARCH enhanced with complete author names
NEWS	25	JUL 02	CHEMCATS accession numbers revised
NEWS	26	JUL 02	CA/CAPplus enhanced with utility model patents from China
NEWS EXPRESS	29	JUNE 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

Best Available Copy

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:05:59 ON 09 JUL 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'REGISTRY' ENTERED AT 08:07:01 ON 09 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 JUL 2007 HIGHEST RN 941671-52-9

DICTIONARY FILE UPDATES: 8 JUL 2007 HIGHEST RN 941671-52-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10582838.str



chain nodes :

11 12 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37
38 39

ring nodes :

1 2 3 4 5 6 7 8 9 13 14 15 16 17 18

chain bonds :

1-33 2-19 3-34 4-11 8-28 9-27 11-12 12-13 12-35 12-36 14-26 15-39 16-38
17-37 18-25 19-20 19-21 21-22 22-23 22-31 22-32 23-24 23-29 23-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 13-14 13-18 14-15 15-16 16-17
17-18

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-11 5-6 5-7 6-9 7-8 11-12 19-20 19-21 21-22
23-24

exact bonds :

1-33 2-19 3-34 8-9 8-28 9-27 12-13 12-35 12-36 14-26 15-39 16-38 17-37
18-25 22-23 22-31 22-32 23-29 23-30

normalized bonds :

13-14 13-18 14-15 15-16 16-17 17-18

isolated ring systems :

containing 1 : 13 :

Match level :

Best Available Copy

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 11:CLASS
12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS
29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 35:CLASS 36:CLASS
37:CLASS 38:CLASS 39:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 08:07:20 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1 TO ITERATE

100.0% PROCESSED 1 ITERATIONS

0 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1 TO 80

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 08:07:24 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 43 TO ITERATE

100.0% PROCESSED 43 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

L3 3 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

172.10 172.52

FILE 'CAPLUS' ENTERED AT 08:07:29 ON 09 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

Best Available Copy

FILE COVERS 1907 - 9 Jul 2007 VOL 147 ISS 3

FILE LAST UPDATED: 8 Jul 2007 (20070708/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 full

L4 9 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:410774 CAPLUS

DOCUMENT NUMBER: 146:421985

TITLE: Preparation of isotopically substituted (deuterated)
(fused) imidazopyridines for the treatment of
gastrointestinal disorders

INVENTOR(S): Kohl, Bernhard; Zimmermann, Peter Jan; Zech, Karl;
Buhr, Wilm; Palmer, Andreas; Brehm, Christof; Chiesa,
Maria Vittoria; Kromer, Wolfgang; Postius, Stefan;
Simon, Wolfgang-Alexander; Holst, Hans Christof

PATENT ASSIGNEE(S): Altana Pharma AG, Germany

SOURCE: PCT Int. Appl., 62pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007039464	A1	20070412	WO 2006-EP66544	20060920
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			


PRIORITY APPLN. INFO.:

EP 2005-108764 A 20050922


EP 2006-101701 A 20060215

OTHER SOURCE(S): MARPAT 146:421985

GI



I



AB Title compds. [I; R1 = H, alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, alkoxyalkyl, alkenyl, alkynyl, fluoroalkyl, hydroxyalkyl; R2 = H, alkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, hydroxyalkyl, halo, alkenyl, alkynyl, fluoroalkyl, cyanomethyl; R3 = H, halo, alkyl, fluoroalkyl, CO₂H, alkoxyalkyl, hydroxyalkyl, alkoxyalkyl, fluoroalkoxyalkyl, etc.; R4, R5 = H, R6 = (substituted) Ph; or R4R5 = CHR₇CHR₈; R7, R8 = H, OH, alkoxy, cycloalkoxy, cycloalkylalkoxy, alkoxyalkoxy, fluoroalkoxy, hydroxyalkoxy, etc.; or R4 = H, R5R6 = Q1; Z = CHR₁₁, CHR₁₁CHR₁₂; R9 = H, alkyl, hydroxyalkyl, alkoxy, alkenyloxy, aryloxy, etc.; R10 = H, alkyl, alkoxy, alkoxyalkyl, halo, CF₃, OH; R11, R12 = H, alkyl, alkenyl, OH, alkoxy, alkylcarbonylamino, etc.; X = O, NH; ≥1 of the H atoms of R1-R6 or of the core structure is replaced with D], were prepared. Thus, Me 8-[(2,6-dimethylphenyl)dideuteromethylamino]-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate (preparation given) was heated 1 h with ethanolamine to give 73% 8-[(2,6-dimethylphenyl)dideuteromethylamino]-N-(2-hydroxyethyl)-2,3-dimethylimidazo-6-carboxamide. The latter inhibited H⁺/K⁺-ATPase with -lg IC₅₀ = 6.0.


IT 934248-01-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(claimed compound; preparation of isotopically substituted (deuterated) (fused) imidazopyridines for the treatment of gastrointestinal disorders)

RN 934248-01-8. CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[(2,6-dimethylphenyl)methyl-d₂]amino]-N-(2-hydroxyethyl)-2,3-dimethyl- (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Best Available Copy

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1173242 CAPLUS

DOCUMENT NUMBER: 145:489255

TITLE: Preparation of mutual prodrug compounds for use as antiinflammatory agents with gastrointestinal protective activity

INVENTOR(S): Brehm, Christof; Klein, Thomas; Buhr, Wilm; Chiesa, Maria Vittoria; Palmer, Andreas; Zimmermann, Peter Jan; Simon, Wolfgang-Alexander; Kromer, Wolfgang; Postius, Stefan; Grundler, Gerhard

PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 70pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006117315	A1	20061109	WO 2006-EP61850	20060426
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				


PRIORITY APPLN. INFO.:

EP 2005-103581

A 20050429

OTHER SOURCE(S): MARPAT 145:489255

GI




AB The invention concerns A-Y-X-z-C(O)O-B (A is derived from ACO₂H having antipyretic, analgesic, antiphlogistic and/or antiinflammatory properties; B is derived from HOB that are potassium competitive acid blockers; X = bond or linker (e.g. (un)substituted -(CH₂)_nOm(CH₂)_pOq(CH₂)_r (n = 1-7; m = 0, 1; p = 0-7; q = 0, 1; r = 0-7)); Y = -C(O)O- with A attached to the carbonyl carbon; z = bond, -O-, -CHR₁- or -NR₁- (R₁ = H or C1-4 alkyl); or X, Y and z together form a bond; addnl. details including provisos are given in the claims; e.g. (S)-2-(6-methoxynaphthalen-2-yl)propionic acid 3-[[[(7R,8R,9R)-2,3-dimethyl-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-8-yl]oxy]carbonyl]propyl ester

(shown as I)) and their salts. The compds. are prodrugs and exhibit in the human and/or animal body antipyretic, analgesic, antiphlogistic and/or antiinflammatory activity as well as gastric acid secretion inhibiting and therefore gastro and intestinal protective activity. Although the methods of preparation are not claimed, preps. and/or characterization data for 23 examples of I and similar compds. are included. For example, I was prepared from (S)-2-(6-methoxynaphthalen-2-yl)propionic acid and 4-hydroxybutyric acid (7R,8R,9R)-2,3-dimethyl-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-8-yl ester in THF using DMAP and toluenesulfonyl chloride. Data are provided for the inhibition of gastric acid secretion by 2 examples of I or similar compds. and for inhibition of COX-1/2 by 11 examples of I or similar compds.

IT 248919-64-4, 2,3-Dimethyl-8-[(2,6-dimethylbenzyl)amino]-6-[N-(2-hydroxyethyl)aminocarbonyl]imidazo[1,2-a]pyridine
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of mutual prodrug compds. for use as antiinflammatory agents with gastrointestinal protective activity)

RN 248919-64-4 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[(2,6-dimethylphenyl)methyl]amino]-N-(2-hydroxyethyl)-2,3-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:570894 CAPLUS

DOCUMENT NUMBER: 143:83527

TITLE: Crystalline forms of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethylimidazo[1,2-a]pyridine-6-carboxamide mesylate salt

INVENTOR(S): Lilljequist, Lars; Lindkvist, Maria; Nordberg, Peter; Pettersson, Ursula; Sebhathu, Tesfai

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005058895	A1	20050630	WO 2004-SE1909	20041216
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

Best Available Copy

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004299435 A1 20050630 AU 2004-299435 20041216
 CA 2549144 A1 20050630 CA 2004-2549144 20041216
 EP 1697360 A1 20060906 EP 2004-809082 20041216

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU

CN 1894246 A 20070110 CN 2004-80037988 20041216
 BR 2004017640 A 20070327 BR 2004-17640 20041216
 JP 2007514744 T 20070607 JP 2006-545292 20041216

US 2007112021 A1 20070517 US 2006-582838 20060614
 NO 2006003309 A 20060914 NO 2006-3309 20060717

PRIORITY APPLN. INFO.:

SE 2003-3451 A 20031218
 WO 2004-SE1909 W 20041216

AB The present invention relates to novel crystalline forms of 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethylimidazo[1,2-a]pyridine-6-carboxamide mesylate salt (I) and to mixture thereof. Further, the present invention also relates to processes for obtaining them, the use of the compds. for the treatment of gastrointestinal disorders, and pharmaceutical compns. containing them. 2,3-Dimethyl-8-(2,6-dimethylbenzylamino)-N-hydroxyethylimidazo[1,2-a]pyridine-6-carboxamide was treated with methanesulfonic acid in EtOH to give crystals of I Form A. The compound was characterized by x-ray crystallog.

IT 855998-67-3P

RL: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(crystalline forms of (dimethylbenzylamino)hydroxyethylimidazopyridinecarboxamide)


RN 855998-67-3 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[[(2,6-dimethylphenyl)methyl]amino]-N-(2-hydroxyethyl)-2,3-dimethyl-, monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 248919-64-4


CMF C21 H26 N4 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S




IT 248919-64-4

RL: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT
(Reactant or reagent); USES (Uses)

(crystalline forms of (dimethylbenzylamino)hydroxyethylimidazopyridinecarbox
amide)

RN 248919-64-4 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[2,6-
dimethylphenyl)methyl]amino]-N-(2-hydroxyethyl)-2,3-dimethyl- (9CI) (CA
INDEX NAME)



REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:409313 CAPLUS

DOCUMENT NUMBER: 142:457095

TITLE: Imidazo [1,2-a] pyridine derivatives for the treatment
of silent gastro-esophageal reflux

INVENTOR(S): Fernstroem, Paula; Hasselgren, Goeran

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041961	A1	20050512	WO 2004-SE1589	20041103
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
 SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
 NE, SN, TD, TG


AU 2004285394	A1	20050512	AU 2004-285394	20041103
CA 2544325	A1	20050512	CA 2004-2544325	20041103
EP 1682133	A1	20060726	EP 2004-800252	20041103

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR, IS

CN 1874772	A	20061206	CN 2004-80032415	20041103
NO 2006002570	A	20060803	NO 2006-2570	20060602
PRIORITY APPLN. INFO.:			US 2003-517125P	P 20031103
			WO 2004-SE1589	W 20041103

OTHER SOURCE(S): MARPAT 142:457095

GI



I

AB The present invention relates to a new method of treatment of sleep disturbance due to silent gastro-esophageal reflux. The invention further relates to the use of potassium-competitive acid blockers (P-CAB's) which inhibit the enzyme responsible for gastric acid secretion (H⁺/K⁺-ATPase). In particular, the present invention relates to the use of certain imidazo (1,2-a)pyridines derivs. (I wherein R1 = H, Me or Et; R2 = Me or Et; R3 and R4 = H, C1-6 alkyl, hydroxylated C1-6 alkyl or halogen; R5 = H or halogen; R6 and R7 = H, C1-6 alkyl, hydroxylated C1-6 alkyl or C1-6 alkoxy-substituted C1-6 alkyl and X = NH or O) in said treatment.


IT 248919-64-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(imidazo[a]pyridine derivs. for treatment of silent gastro-esophageal reflux and sleep disturbances in relation to potassium-competitive acid secretion blockade)

RN 248919-64-4 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[[2,6-dimethylphenyl)methyl]amino]-N-(2-hydroxyethyl)-2,3-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1059201 CAPLUS

DOCUMENT NUMBER: 142:32977

TITLE: Pharmaceutical combinations of a proton pump inhibitor and a compound which modifies gastrointestinal motility

INVENTOR(S): Zimmermann, Peter Jan; Chiesa, M. Vittoria; Palmer, Andreas; Brehm, Christof; Klein, Thomas; Senn-Bilfinger, Joerg; Simon, Wolfgang-Alexander; Kromer, Wolfgang; Grundler, Gerhard; Hanauer, Guido; Buhr, Wilm; Postius, Stefan

PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 102 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004105795	A1	20041209	WO 2004-EP50936	20040526
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004243444	A1	20041209	AU 2004-243444	20040526
CA 2526566	A1	20041209	CA 2004-2526566	20040526
EP 1644043	A1	20060412	EP 2004-741658	20040526
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006528231	T	20061214	JP 2006-530222	20040526
US 2006241134	A1	20061026	US 2005-557414	20051118
NO 2005005968	A	20051215	NO 2005-5968	20051215
PRIORITY APPLN. INFO.:			EP 2003-11875	A 20030527
			EP 2004-102304	A 20040525


WO 2004-EP50936 W 20040526

AB The invention relates to the combination of certain active compds. from the acid pump antagonist class and compds. which modify gastrointestinal motility. The acid pump antagonist class is selected from a tricyclic imidazopyridine and the gastrointestinal motility modifier is selected from a 5-HT-(partial)-agonist/antagonist.

IT 248919-64-4
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical combinations of proton pump inhibitor and modifier of gastrointestinal motility)

RN 248919-64-4 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[2,6-dimethylphenyl)methyl]amino]-N-(2-hydroxyethyl)-2,3-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:913040 CAPLUS

DOCUMENT NUMBER: 139:375018

TITLE: Combinations containing proton pump inhibitors for the treatment of airway disorders

INVENTOR(S): Hanauer, Guido; Kromer, Wolfgang; Postius, Stefan; Simon, Wolfgang-Alexander

PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003094967	A2	20031120	WO 2003-EP4653	20030503
WO 2003094967	A3	20040401		
W: AE, AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, SG, TN, UA, US, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
AU 2003227710	A1	20031111	AU 2003-227710	20030503
CA 2484272	A1	20031120	CA 2003-2484272	20030503
EP 1506016	A2	20050216	EP 2003-725140	20030503

Best Available Copy

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

BR 2003009808	A	20050301	BR 2003-9808	20030503
CN 1652822	A	20050810	CN 2003-810400	20030503
JP 2005528418	T	20050922	JP 2004-503050	20030503
IN 2004MN00536	A	20050513	IN 2004-MN536	20040928
US 2005222193	A1	20051006	US 2004-513598	20041105
NO 2004005343	A	20041206	NO 2004-5343	20041206
PRIORITY APPLN. INFO.:			EP 2002-10305	A 20020507
			WO 2003-EP4653	W 20030503

AB A method for treating airway disorders comprises a reversible proton pump inhibitor and an airway therapeutic to be taken simultaneously (as a fixed oral combination) or in succession (one directly after the other or else within a relatively large time span). The reversible proton pump inhibitor is, e.g., Soraprazan or its salt, and the airway therapeutic is, e.g., Ciclesonide.


IT 248919-64-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(oral combination of reversible proton pump inhibitors and airway therapeutics for treatment of airway disorders)

RN 248919-64-4 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[2,6-dimethylphenyl)methyl]amino]-N-(2-hydroxyethyl)-2,3-dimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:637503 CAPLUS

DOCUMENT NUMBER: 137:190728

TITLE: Novel modified release formulation containing carboxamide derivatives for inhibition of secretion of gastric acid

INVENTOR(S): Juppo, Anne

PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.

SOURCE: PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064118	A1	20020822	WO 2002-SE227	20020208
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2434542	A1	20020822	CA 2002-2434542	20020208
AU 2002230344	A1	20020828	AU 2002-230344	20020208
EP 1361868	A1	20031119	EP 2002-711597	20020208


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

CN 1491105	A	20040421	CN 2002-804906	20020208
CN 1491104	A	20040421	CN 2002-804914	20020208
JP 2004518708	T	20040624	JP 2002-563914	20020208
NZ 526993	A	20050128	NZ 2002-526993	20020208
AT 324871	T	20060615	AT 2002-710645	20020208
PT 1368006	T	20060831	PT 2002-710645	20020208
ES 2261643	T3	20061116	ES 2002-2710645	20020208
ZA 2003005944	A	20050311	ZA 2003-5944	20030731
US 2004067252	A1	20040408	US 2003-467723	20030811

PRIORITY APPLN. INFO.:

SE 2001-477	A	20010213
SE 2001-478	A	20010213
WO 2002-SE227	W	20020208

OTHER SOURCE(S): MARPAT 137:190728
GI



AB A multiparticulate (particle size < 300 μm), modified-release solid dispersion formulation comprises (i) a drug substance having a pH-dependent solubility, i.e., compound I ($R_1 = \text{H, Me, Et}$; $R_2 = \text{Me, Et}$; $R_3, R_4 = \text{H, C1-6 alkyl, hydroxylated C1-6 alkyl, halogen}$; $R_5 = \text{H, halogen}$; $R_6, R_7 = \text{H, C1-6 alkyl, hydroxylated C1-6 alkyl, C1-6 alkoxy-substituted C1-6 alkyl}$; $X = \text{NH, O}$) or a pharmaceutically acceptable salt thereof; (ii) a hydrophobic matrix former which is a water-insol., non-swelling amphiphilic lipid; and (iii) a hydrophilic matrix former which is a meltable, water-soluble excipient. The weight ratio of hydrophobic matrix former/hydrophilic matrix former is ≥ 1 and the particle size is less than 300 μm . Also a unit dosage form of the compound I, as well as a process for its preparation, and the use of the formulation and unit dosage form for inhibiting the secretion of gastric acid are described. For example, multiparticulate, modified-release formulation was prepared by dissolving 1 g of 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)imidazo[1,2-a]pyridine-6-carboxamide mesylate in a melt of 4 g myristic acid at

Best Available Copy


90° and adding 2 g of polyethylene glycol 4000 (PEG 4000) into the melt. The melted mixture was atomized at 90° and the particles were collected into a vessel which was kept on ice. The resulted particles were spherical and < 300 µm in size. The amount of 3 g of particles were blended with 5.85 g microcryst. cellulose and 0.016 g sodium stearyl fumarate and compressed into 450 mg tablets. The dissoln. of tablets was 52-56% in 3 h.

IT 248919-64-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release formulation containing imidazopyridine carboxamide derivs. for inhibition of gastric acid secretion)

RN 248919-64-4 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[2,6-dimethylphenyl)methyl]amino]-N-(2-hydroxyethyl)-2,3-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:185119 CAPLUS

DOCUMENT NUMBER: 136:249369

TITLE: Process for preparing a substituted imidazopyridine compound

INVENTOR(S): Elman, Bjoern; Erback, Silke; Thiemermann, Eric

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020523	A1	20020314	WO 2001-SE1897	20010905
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2419764	A1	20020314	CA 2001-2419764	20010905

Best Available Copy

AU 200184594	A	20020322	AU 2001-84594	20010905
EP 1317455	A1	20030611	EP 2001-963665	20010905
EP 1317455	B1	20040804		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001013602	A	20030715	BR 2001-13602	20010905
HU 200302277	A2	20031028	HU 2003-2277	20010905
HU 225459	B1	20061228		
JP 2004508371	T	20040318	JP 2002-525144	20010905
AT 272637	T	20040815	AT 2001-963665	20010905
NZ 524302	A	20040827	NZ 2001-524302	20010905
PT 1317455	T	20041130	PT 2001-963665	20010905
EE 200300090	A	20041215	EE 2003-90	20010905
ES 2223906	T3	20050301	ES 2001-1963665	20010905
CZ 294957	B6	20050413	CZ 2003-643	20010905
RU 2275372	C2	20060427	RU 2003-104987	20010905
ZA 2003001171	A	20040318	ZA 2003-1171	20030212
IN 2003MN00220	A	20060505	IN 2003-MN220	20030214
NO 2003001046	A	20030505	NO 2003-1046	20030306
US 2004039013	A1	20040226	US 2003-363806	20030627
US 6900324	B2	20050531		
HK 1054388	A1	20050408	HK 2003-106657	20030916
US 2006063797	A1	20060323	US 2005-107352	20050414
PRIORITY APPLN. INFO.:			SE 2000-3186	A 20000907
			WO 2001-SE1897	W 20010905
			US 2003-363806	A1 20030627

OTHER SOURCE(S): MARPAT 136:249369
GI




AB Present invention provides a new process for large-scale preparation of substituted imidazopyridine compound of formula (I), wherein R1 = C1-6 alkoxy or NH2 group, comprising the step of reacting a compound of formula (II) with a 3-halo-2-butanone compound in cyclohexanone. Thus, 5.1 g 5,6-diaminonicotinic acid Me ester, 50 mL cyclohexanone, and 3.9 mL bromobutanone were agitated at 100° for 2.5 h to give Me 8-amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate.

IT 248919-64-4P
RL: IMF (Industrial manufacture); PREP (Preparation)
(process for preparing a substituted imidazopyridine compound)

RN 248919-64-4 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[[(2,6-dimethylphenyl)methyl]amino]-N-(2-hydroxyethyl)-2,3-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1999:708770 CAPLUS

DOCUMENT NUMBER: 131:322617

TITLE: Preparation of imidazopyridines which inhibit gastric acid secretion

INVENTOR(S): Amin, Kosrat; Dahlstrom, Michael; Nordberg, Peter; Starke, Ingemar

PATENT ASSIGNEE(S): Astra AB, Swed.

SOURCE: PCT Int. Appl., 77 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9955706	A1	19991104	WO 1999-SE663	19990423
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TW 490466	B	20020611	TW 1999-88106129	19990416
TW 250159	B	20060301	TW 1999-88106128	19990416
CA 2329922	A1	19991104	CA 1999-2329922	19990423
CA 2329922	C	20060411		
AU 9943007	A	19991116	AU 1999-43007	19990423
AU 769190	B2	20040122		
BR 9909996	A	20001226	BR 1999-9996	19990423
EP 1073657	A1	20010207	EP 1999-947038	19990423
EP 1073657	B1	20051207		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
TR 200003149	T2	20010321	TR 2000-200003149	19990423
TR 200003176	T2	20010321	TR 2000-200003176	19990423
HU 200102425	A2	20011128	HU 2001-2425	19990423
EE 200000664	A	20020415	EE 2000-664	19990423
JP 2002513025	T	20020508	JP 2000-545865	19990423
JP 3692034	B2	20050907		

Best Available Copy

TR 200102612	T2	20020621	TR 2001-200102612	19990423
TR 200102728	T2	20020621	TR 2001-200102728	19990423
CZ 292567	B6	20031015	CZ 2000-3982	19990423
NZ 507639	A	20040130	NZ 1999-507639	19990423
CZ 293977	B6	20040915	CZ 2000-3981	19990423
RU 2238271	C2	20041020	RU 2000-127019	19990423
EP 1491542	A2	20041229	EP 2004-23090	19990423
EP 1491542	A3	20050105		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY				
EP 1491543	A1	20041229	EP 2004-23091	19990423
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY				
AT 312101	T	20051215	AT 1999-947038	19990423
ES 2249913	T3	20060401	ES 1999-947037	19990423
ES 2252975	T3	20060516	ES 1999-947038	19990423
US 6313137	B1	20011106	US 1999-319973	19990614
IN 2000MN00497	A	20050318	IN 2000-MN497	20001012
ZA 2000005796	A	20020118	ZA 2000-5796	20001018
ZA 2000005797	A	20020118	ZA 2000-5797	20001018
MX 2000PA10239	A	20010405	MX 2000-PA10239	20001019
NO 2000005450	A	20001222	NO 2000-5450	20001027
NO 317262	B1	20040927		
HK 1033317	A1	20060630	HK 2001-104064	20010613
HK 1036984	A1	20050429	HK 2001-107857	20011108
PRIORITY APPLN. INFO.:				
			SE 1998-1526	A 19980429
			EP 1999-947037	A3 19990423
			EP 1999-947038	A3 19990423
			WO 1999-SE663	W 19990423

OTHER SOURCE(S): MARPAT 131:322617
GI



AB The title compds. [I; R1 = H, Me, CH₂OH; R2 = Me, Et; R3 = H, alkyl, halo, etc.; R4 = H, alkyl, halo, etc.; R5 = H, halo; R6, R7 = H, alkyl, hydroxylated alkyl, etc.; X = NH, O] which inhibit exogenously or endogenously stimulated gastric acid secretion (no data) and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases, and for treatment or prophylaxis of conditions involving infection by *Helicobacter pylori* of human gastric mucosa, were prepared. Thus, reacting Et 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylate with propylamine in the presence of a cat. amount of NaCN in MeOH afforded 42% I [R1 = R2 = R4 = Me; R3 = Et; R5 = R7 = H; R6 = Pr]. In general, compds. I are effective at 5-1000 mg/day.


IT 248919-64-4P

Best Available Copy

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazopyridines which inhibit gastric acid secretion)

RN 248919-64-4 CAPLUS

CN Imidazo[1,2-a]pyridine-6-carboxamide, 8-[[2,6-dimethylphenyl)methyl]amino]-N-(2-hydroxyethyl)-2,3-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 08:05:59 ON 09 JUL 2007)

FILE 'REGISTRY' ENTERED AT 08:07:01 ON 09 JUL 2007

L1 STRUCTURE UPLOADED
L2 0 S L1
L3 3 S L1 FULL

FILE 'CAPLUS' ENTERED AT 08:07:29 ON 09 JUL 2007

L4 9 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
47.90	220.42

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-7.02	-7.02

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 08:08:10 ON 09 JUL 2007

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.